Generating tomorrow’s medicines today
We can deliver RNA therapeutics to specific cells that are currently inaccessible.
Safe & Tolerable
The pharmacokinetics of eRNA and our versatile delivery platform offer a more tolerable profile and lower dosing than existing nucleic acid technologies in preclinical studies.
We engineer our eRNA and nanoparticles to enable therapeutically relevant thresholds (e.g., route of administration, cell type, and pharmacokinetics) for a diverse set of applications.
We strive to deliver medicines to the right cells, at the right dose.
Our platform is designed to enable extended RNA pharmacokinetics, providing the potential for durable long-lasting medicines that reduce the clinical burden and cost of repeat dosing.